2024-12-16-德勤-GenAI正在改变医疗技术的游戏规则吗_14页_3mb

Summary of Generative AI in MedTech Based on Deloitte Research

Key Findings

Deloitte research indicates that Generative AI (GenAI) is beginning to deliver value to medtech companies, with applications in areas such as product development and IT/cybersecurity. Specifically, 42% of surveyed executives report benefits in product development, and 35% in IT and cybersecurity. GenAI could enable cost efficiencies of 6% to 12% of total revenue in the next 2-3 years, translating to potential savings of up to $3.2 billion for a $26 billion revenue company, including reductions in selling, general, and administrative (SG&A) costs, cost of goods sold (COGS), and research and development (R&D) expenses. For example, R&D cost savings could reach 20% over this period.

Current Value Realization

GenAI is already delivering tangible benefits across functions, with use cases including digital asset management, people analytics, scientific writing, and cybersecurity. Companies like Siemens Healthineers and Meticuly have demonstrated efficiency gains through AI implementation in areas such as cost reduction and personalized technology.

Future Potential

The string-of-pearls approach, combining GenAI with other AI, data, and digital tools, could drive transformative value by automating workflows, enhancing customer engagement, and optimizing supply chains. Estimated cost efficiencies range from 5% to 12% across various cost categories, with potential for compound effects in commercial operations and manufacturing.

Building Blocks for Maximizing Value

To scale GenAI effectively, medtech companies should focus on six key areas:

1. Craft a strategic blueprint aligned with business objectives.
2. Build operational structures, such as a Center of Excellence, for alignment and resource management.
3. Prioritize value realization through disciplined evaluation and adoption of AI use cases.
4. Develop technology capabilities, including platform selection and ecosystem partnerships.
5. Foster new ways of working, emphasizing human augmentation and AI literacy training.
6. Promote responsible AI use with governance for data privacy, security, and ethical deployment.

Conclusion

Medtech is at an inflection point, with GenAI poised to drive significant transformation. Companies should make bold plays to integrate GenAI into their operations, potentially unlocking efficiency, innovation, and cost savings, while addressing regulatory and ethical considerations through systematic approaches.